AU2015252184B2 - A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents

A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline Download PDF

Info

Publication number
AU2015252184B2
AU2015252184B2 AU2015252184A AU2015252184A AU2015252184B2 AU 2015252184 B2 AU2015252184 B2 AU 2015252184B2 AU 2015252184 A AU2015252184 A AU 2015252184A AU 2015252184 A AU2015252184 A AU 2015252184A AU 2015252184 B2 AU2015252184 B2 AU 2015252184B2
Authority
AU
Australia
Prior art keywords
compound
sap
disease
formula
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015252184A
Other languages
English (en)
Other versions
AU2015252184A1 (en
Inventor
Alexis Denis
Olivier Mirguet
Jerome Toum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2015252184A1 publication Critical patent/AU2015252184A1/en
Application granted granted Critical
Publication of AU2015252184B2 publication Critical patent/AU2015252184B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2015252184A 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline Ceased AU2015252184B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1407506.3 2014-04-29
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (2)

Publication Number Publication Date
AU2015252184A1 AU2015252184A1 (en) 2016-10-27
AU2015252184B2 true AU2015252184B2 (en) 2017-11-02

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015252184A Ceased AU2015252184B2 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Country Status (26)

Country Link
US (3) US9701668B2 (enExample)
EP (1) EP3137457B1 (enExample)
JP (1) JP6445046B2 (enExample)
KR (1) KR20160145617A (enExample)
CN (1) CN106459016B (enExample)
AR (1) AR100204A1 (enExample)
AU (1) AU2015252184B2 (enExample)
BR (1) BR112016025129A2 (enExample)
CA (1) CA2947060C (enExample)
CL (1) CL2016002721A1 (enExample)
CR (1) CR20160508A (enExample)
DO (1) DOP2016000292A (enExample)
EA (1) EA032129B1 (enExample)
ES (1) ES2731253T3 (enExample)
GB (1) GB201407506D0 (enExample)
IL (2) IL248249A0 (enExample)
MA (1) MA39406B1 (enExample)
MX (1) MX2016014246A (enExample)
MY (1) MY191088A (enExample)
PE (1) PE20161558A1 (enExample)
PH (1) PH12016502006B1 (enExample)
SG (1) SG11201608371RA (enExample)
TW (1) TWI676624B (enExample)
UA (1) UA119871C2 (enExample)
UY (1) UY36098A (enExample)
WO (1) WO2015165833A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) * 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051836A1 (en) * 2001-12-14 2003-06-26 F. Hoffmann-La Roche Ag Prodrugs to d-prolines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2182203T3 (es) 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
JP2006526612A (ja) 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
KR20080004571A (ko) 2005-04-12 2008-01-09 메이지 세이카 가부시키가이샤 2-티오에테닐 카바페넴 유도체
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051836A1 (en) * 2001-12-14 2003-06-26 F. Hoffmann-La Roche Ag Prodrugs to d-prolines

Also Published As

Publication number Publication date
TWI676624B (zh) 2019-11-11
WO2015165833A1 (en) 2015-11-05
CA2947060A1 (en) 2015-11-05
CN106459016A (zh) 2017-02-22
UA119871C2 (uk) 2019-08-27
US20180099955A1 (en) 2018-04-12
US20170267665A1 (en) 2017-09-21
JP6445046B2 (ja) 2018-12-26
CR20160508A (es) 2017-03-10
DOP2016000292A (es) 2017-11-15
IL279120A (en) 2021-01-31
ES2731253T3 (es) 2019-11-14
EA201692185A1 (ru) 2017-06-30
IL248249A0 (en) 2016-11-30
US9873686B2 (en) 2018-01-23
EP3137457B1 (en) 2019-04-17
US20160075694A1 (en) 2016-03-17
EP3137457A1 (en) 2017-03-08
MA39406B1 (fr) 2018-04-30
JP2017514829A (ja) 2017-06-08
GB201407506D0 (en) 2014-06-11
US10597385B2 (en) 2020-03-24
CL2016002721A1 (es) 2017-01-20
EA032129B1 (ru) 2019-04-30
BR112016025129A2 (pt) 2017-08-15
PH12016502006A1 (en) 2016-12-19
TW201625598A (zh) 2016-07-16
PE20161558A1 (es) 2017-01-06
UY36098A (es) 2015-11-30
MX2016014246A (es) 2017-02-06
AU2015252184A1 (en) 2016-10-27
AR100204A1 (es) 2016-09-21
US9701668B2 (en) 2017-07-11
KR20160145617A (ko) 2016-12-20
MA39406A1 (fr) 2017-07-31
CN106459016B (zh) 2019-11-01
MY191088A (en) 2022-05-30
CA2947060C (en) 2023-09-26
PH12016502006B1 (en) 2016-12-19
SG11201608371RA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
Denny et al. Recent developments in targeting protein misfolding diseases
JP2018177788A (ja) Ｎｔｃｐ阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびｎｒｌｐ３インフラマソーム関連疾患の治療
US10597385B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
WO2023165459A1 (en) Compounds as sars-cov-2 inhibitors
Tanaka et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
AU2015237253A1 (en) Compositions and methods for treating neurodegenerative diseases
US10328052B2 (en) D-proline derivatives as SAP depleting agent
CN114025766A (zh) 用于抑制gapdh的噁噻嗪化合物
WO2022029810A1 (en) Peptides able to bind angiotensin-converting enzyme 2 (ace2) and medical uses thereof
EP4178945B1 (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40067738A (en) Oxathiazin compounds for inhibiting gapdh
HK40117187A (en) Therapy using htcp inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired